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ABSTRACT Urinary tract infections (UTIs) are predominantly caused by uropathogenic
Escherichia coli (UPEC). UPEC pathogenesis requires passage through a severe population
bottleneck involving intracellular bacterial communities (IBCs) that are clonal expansions
of a single invading UPEC bacterium in a urothelial superficial facet cell. IBCs occur only
during acute pathogenesis. The bacteria in IBCs form the founder population that devel-
ops into persistent extracellular infections. Only a small fraction of UPEC organisms pro-
ceed through the IBC cycle, regardless of the inoculum size. This dramatic reduction in
population size precludes the utility of genomic mutagenesis technologies for identify-
ing genes important for persistence. To circumvent this bottleneck, we previously identi-
fied 29 positively selected genes (PSGs) within UPEC and hypothesized that they con-
tribute to virulence. Here, we show that 8 of these 29 PSGs are required for fitness
during persistent bacteriuria. Conversely, 7/8 of these PSG mutants showed essentially
no phenotype in acute UTI. Deletion of the PSG argI leads to arginine auxotrophy. Rela-
tive to the other arg genes, argI in the B2 clade (which comprises most UPEC strains) of
E. coli has diverged from argI in other E. coli clades. Replacement of argI in a UPEC strain
with a non-UPEC argI allele complemented the arginine auxotrophy but not the persis-
tent bacteriuria defect, showing that the UPEC argI allele contributes to persistent infec-
tion. These results highlight the complex roles of metabolic pathways during infection
and demonstrate that evolutionary approaches can identify infection-specific gene func-
tions downstream of population bottlenecks, shedding light on virulence and the ge-
netic evolution of pathogenesis.
IMPORTANCE Uropathogenic Escherichia coli (UPEC) is the most common cause
of human urinary tract infection (UTI). Population bottlenecks during early stages
of UTI make high-throughput screens impractical for understanding clinically im-
portant later stages of UTI, such as persistence and recurrence. As UPEC is hy-
pothesized to be adapted to these later pathogenic stages, we previously identi-
fied 29 genes evolving under positive selection in UPEC. Here, we found that 8
of these genes, including argI (which is involved in arginine biosynthesis), are
important for persistence in a mouse model of UTI. Deletion of argI and other
arginine synthesis genes resulted in (i) arginine auxotrophy and (ii) defects in
persistent UTI. Replacement of a B2 clade argI with a non-B2 clade argI comple-
mented arginine auxotrophy, but the resulting strain remained attenuated in its
ability to cause persistent bacteriuria. Thus, argI may have a second function
during UTI that is not related to simple arginine synthesis. This study demon-
strates how variation in metabolic genes can impact virulence and provides in-
sight into the mechanisms and evolution of bacterial virulence.
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Urinary tract infections (UTIs) are among the most common bacterial infections ofhumans, affecting over half of all women and accounting for $2.5 billion in
annual health care-related expenses in the United States (1, 2). Uropathogenic Esche-
richia coli (UPEC) accounts for the majority of community-acquired UTIs, typically acute
uncomplicated cystitis (2, 3). Unfortunately, after an initial acute UTI, 25% of women
experience at least one episode of recurrent UTI (rUTI) within 6 months of the initial
infection (4, 5). While in some patients acute UTIs resolve within a week, other patients
can develop chronic recurrent cystitis even despite treatment (6). Further, frequent
empirical antimicrobial treatment of acute UTIs and prophylactic antimicrobial treat-
ment to prevent rUTIs has resulted in the emergence and global dissemination of
multidrug-resistant UPEC (7–9).
Experimental mouse models of UTI are able to mimic many of the known clinical
manifestations of human UTIs, including acute cystitis, recurrent UTI, and chronic
cystitis (10–14). During acute UTI, UPEC employs the FimH adhesin of the type 1 pilus
to invade urothelial superficial facet cells via an endocytic mechanism (10–15). Follow-
ing invasion, some UPEC organisms evade host cell exocytic mechanisms, escape the
endocytic vesicle, and rapidly replicate to form dense clusters (1,000 to 10,000
CFU/epithelial cell) of clonal cytoplasmic bacteria, termed intracellular bacterial com-
munities (IBCs) (16–21). IBCs are resistant to antibiotic treatment and the host immune
response. In addition, quiescent intracellular reservoirs (QIRs) can form in the underly-
ing transitional epithelial cells, comprising clusters of 2 to 12 membrane-bound bac-
teria that are dormant and thereby tolerant of antibiotics and host defenses (22–24).
QIRs can persist for weeks to months, during which time the urine may be sterile;
however, bacteria can reemerge from a QIR to cause a rUTI (25–27). Importantly,
structures similar to IBCs can be found in the urine of human patients suffering from
UTI, further supporting the relevance of experiments with the mouse model (28–31).
Mice with a history of UTI are predisposed to chronic rUTI. In mice, chronic cystitis
occurs downstream of the IBC bottleneck and is defined as an extracellular infection
characterized by persistent, high-titer bacteriuria (104 CFU/ml) and bladder coloniza-
tion (104 CFU/bladder), chronic pyuria, ablation of the terminally differentiated
superficial cells, urothelial hyperplasia, lymphoid follicles, and urothelial necrosis per-
sisting for weeks (10). Mice with a history of chronic cystitis can be cured by antibiotic
treatment; however, they are thereafter sensitized to higher rates of rUTI in subsequent
challenge infections due to bladder remodeling (10, 13, 14). In mice, infection can leave
a molecular imprint resulting in hundreds of differentially expressed genes compared
to the bladders of naive mice; this physiological remodeling results in a predisposition
to rUTI (13). Of note, in humans, the history of UTI is one of the most significant risk
factors predisposing to a rUTI (32, 33).
One of the main experimental hurdles in studying factors important in persistent
UTI and rUTI is the progressive population bottleneck that begins during the initial
acute phase of cystitis. The bacteria within an IBC are clonal (each IBC is descended
from a single invasive UPEC organism), and only 1 of 105 to 106 experimentally
inoculated UPEC organisms forms an IBC (16). Therefore, IBC formation represents
one severe population bottleneck that occurs during acute infection (16). The
formation of QIRs and development of chronic cystitis incur additional bottlenecks,
as measured by random loss of coinoculated, isogenic, differentially marked strains
(16). The mechanisms causing these bottlenecks are not fully defined, but they are
likely related to some combination of bacterial invasion, immune cell killing,
intracellular innate immune responses, competitive growth, and continuous mic-
turition. Because modern unbiased genetic approaches (like signature-tagged mu-
tagenesis or transposon insertion sequencing [Tn-seq] screens) require testing of
high-complexity mutant libraries (i.e., those having a large number of genetically
distinct clones), population bottlenecks (which cause random loss of clones) pre-
vent identification of mutants that exhibit defects downstream of the bottleneck
(34–36). Recently, unbiased global approaches to interrogate UPEC, including com-
parative genomics, transcriptomics, and proteomics, have also been applied to
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analyze factors required for UTI pathogenesis (37–41), though these have not
addressed chronic rUTI.
In silico sequence-based methods provide an alternative approach to identifying
virulence factors that does not suffer from experimental population bottlenecks. UPEC
are hypothesized to be better adapted to the urinary tract than non-UPEC strains. Any
adaptive mutation(s) should be evolving under positive selection; therefore, we and
others have conceptually connected loci under positive selection with virulence-related
genes (42–49). Indeed, FimH, a critical virulence factor for acute UTI and IBC formation,
is evolving under positive selection in UPEC, and identification of individually selected
amino acids has led to fundamental insights into the structure, function, and evolution
of FimH and the importance of a finely tuned conformational equilibrium to its function
in UTIs (48–50). Thus, positive-selection analysis can identify virulence factors (and their
functions) that otherwise might be difficult to study due to population bottlenecks.
We previously used an in silico comparative genomics analysis to identify 29 genes
evolving under positive selection (here referred to as positively selected genes [PSGs])
specifically in UPEC but not other types of E. coli (47). These 29 PSGs are predicted to
contribute to a diverse set of cellular functions, including iron uptake, membrane
protein localization, DNA structure and repair, small-molecule import/export, cell divi-
sion, and arginine metabolism (47); however, their roles in chronic UTI have not been
characterized. Here, we tested the impact of these 29 PSGs on the fitness of UPEC in a
mouse model of UTI, focusing on chronic cystitis (10–12, 51). In total, single gene
deletions of 10 different PSGs had lower fitness in at least one of our in vivo infection
models, with 8 single PSG deletions showing defects during chronic cystitis. Further
analysis of the argI gene (encoding the anabolic ornithine transcarbamoylase) showed
that while arginine biosynthesis is important for in vivo fitness, argI also seems to have
an additional in vivo function during UTI. Specifically, an allelic replacement of a clade
B2 argI with a non-B2 argI allele complements arginine auxotrophy but not in vivo
virulence. In keeping with this, argI from the B2 clade, which comprises the majority of
UPEC strains, is highly diverged from the argI genes found in other E. coli clades (39, 52,
53). Together, these results reveal an unexpected complexity in the importance of
arginine during chronic UTI, which could not have been found from traditional genomic
mutagenesis studies due to the population bottlenecks occurring during in vivo UTI.
They also highlight the value of positive-selection analysis, which has now identified in
vivo-specific roles mediated by allelic variation in both fimH and argI. Finally, our results
suggest that screening for anomalous divergence patterns, a rapid technique amenable
to modern genomic data sets, may be a useful approach to identify other genes
involved in virulence and bacterial evolution.
RESULTS
PSG mutations have little effect on in vitro phenotypes. The primary hypothesis
is that genes under positive selection in UPEC play a role during UTI in vivo. We created
knockouts in each of the 29 previously identified PSGs in UTI89, a prototypical UPEC
clinical isolate. We first tested these mutants for in vitro phenotypes previously shown
to be associated with pathogenesis: (i) type 1 pilus expression and function as mea-
sured by guinea pig red blood cell hemagglutination (HA) assay and (ii) growth in rich
(LB) medium and in pooled filtered human urine (54–56). All the PSG mutants were
indistinguishable from the wild type in all assays with two exceptions (Fig. 1A to C): (i)
the ΔrecC mutant had a general growth defect in both LB and urine (Fig. 1B and C), and
(ii) the ΔargI mutant had a mild growth defect in urine (but not in LB), wherein the cell
density during stationary phase was lower (Fig. 1B and C). Supporting these observa-
tions, deletion of either recC or argI in the UPEC isolate CFT073 was recently shown to
cause an in vitro growth defect in human urine (36).
Multiple PSGs have a role in chronic UTI. We next tested the competitive fitness
of each PSG mutant in a mouse model of chronic UTI, in which naive female 7- to
8-week-old C3H/HeN mice were inoculated with a mixture of 108 CFU each of a PSG
mutant and wild-type UTI89. Infected mice were monitored by urinalysis until 28 days
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post-infection (dpi), at which time the mice were sacrificed and bladder and kidney
burdens were determined (Fig. 2A and Fig. S1 and S2). It was previously shown that
these infections result in two different UTI outcomes: (i) high-titer and chronic infection
and (ii) resolution with or without the formation of QIRs (10). These outcomes are
reliably distinguished by persistently high urine titers (104 CFU/ml), indicating chronic
infection, and low or variable urine titers, indicating resolution; we therefore analyzed
the data for mice with chronic and resolved infections separately (Fig. 2A and Fig. S1
and S2). Eight PSG mutants had chronic cystitis defects (ompC, nepI [previously yicM
{57}], recC, entF, cutE, yjbN, mdtC [previously yegO {58}], and argI), with all being
dramatically outcompeted by the wild type, with median log10(CI) (competitive index)
values below 4 at 28 dpi (indicating that there are 10,000 times more wild-type than
mutant bacteria) (Fig. 2A). Six PSG mutants had fitness defects in the resolved group
(amiA, entD, cutE, yjbN, mdtC, and argI), though due to the lower overall titers, the
median log10(CI) values ranged between 0.2 and 1.29 at 28 dpi (Fig. S1 and S2).
Notably, as strains with mutations in 4 PSGs (cutE, yjbN, mdtC, and argI) had defects in
mice with chronic and resolved infections, there were a total of 10 PSGs that contrib-
uted to some form of long-term persistence in the urinary tract (Fig. 2A and Fig. S2).
Interestingly, single-infection assays showed that, when inoculated individually into
mice, all PSG mutants tested achieved bacterial titers indistinguishable from that of the
wild type at 28 dpi, again with the exception of the ΔrecC mutant (Fig. 2B).
PSG mutants affecting chronic infection have little effect on acute UTI. The
longitudinal urinalysis conducted during the competitive chronic infections revealed
that the median log10(CI)s of the 8 PSG mutants with chronic cystitis defects were
generally close to 0 for the first 24 h (i.e., indistinguishable from that of the wild type)
(Fig. S1). We therefore tested the fitness of the 8 mutant strains in acute-cystitis
experiments: single infections at 6 hpi and competitive infections at 18 hpi (Fig. 2C and
D). Six of the eight mutants were indistinguishable from the wild type in these acute
FIG 1 PSG mutants with growth defects. (A) Mannose-sensitive (phosphate-buffered saline [PBS] only)
and mannose-insensitive (PBS  4% methyl -D-mannopyranoside) HA titers of the PSG mutants. HA
titers are the means and standard deviations for 3 biological replicates. Columns marked with an
asterisk are significantly different from the wild-type value by Student’s t test with a cutoff P value of
0.05. (B) The ΔrecC mutant has growth rate and yield defects when grown in LB medium at 37°C with
aeration. (C) Both the ΔrecC and the ΔargI mutant have growth defects when grown in filter-sterilized
human urine pooled from multiple donors at 37°C with aeration. The ΔrecC mutant has growth rate and
yield defects, while the ΔargI mutant has a growth yield defect. Growth curves are the means of 4
technical replicates and are representative of experiments conducted on different days and with different
batches of LB or urine.
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infections. The most pronounced exception was the ΔrecC mutant, which showed a
substantial defect in both assays (and which was also the mutant with the most severe
in vitro growth defects). Furthermore, consistent with having a mild growth defect in
vitro in urine, the argI mutant had a statistically significant, but quantitatively small,
defect in these acute-infection assays. Interestingly, it was recently found that, in
CFT073, deletion of either recC or yojI resulted in an acute fitness defect (36).
FIG 2 In vivo effects of the PSG mutations. (A) Competitive outcomes of wild-type versus PSG mutant chronic
coinfections at 28 dpi. Circles represent the bladder of a single mouse with chronic cystitis, defined as persistent
high-titer bacteriuria (104 CFU/ml). The horizontal line indicates the median log10(CI). An asterisk indicates that
the median log10(CI) is significantly different from the median log10(CI) of the control (wild type versus wild type)
by the Mann-Whitney U test (P  0.05). Mice that had 1 or more urine samples with low-titer bacteriuria (104
CFU/ml) were analyzed separately, and those data are displayed along with the raw CFU totals and all urine and
kidney data in the supplemental material (Fig. S1 and S2). The total number of infected mice and the frequency
of chronic cystitis of each competitive infection is displayed in the supplemental material (Table S1). In the initial
screen (A), tests with mutants that did not clearly exhibit competitive defects in a 5-mouse group were not
repeated due to ethical concerns. Mutants that did exhibit competitive defects in the initial screen were repeat
tested with at least 1 biological replicate of 10 mice. (B) Bladder colonization and frequency of chronicity caused
by the PSG mutants in single infections at 28 dpi. Closed circles represent a single mouse with persistent high-titer
bacteriuria (104 CFU/ml). Open circles represent a mouse with at least 1 urine sample with low-titer bacteriuria
(104 CFU/ml). The frequency of chronicity for each PSG mutant was determined by dividing the number of mice
with persistent high-titer bacteriuria by the total number of mice infected. An asterisk indicates that the frequency
of chronicity is significantly different from that of the wild type by Fisher’s exact test (P  0.05). At least two
biological replicates with 10 mice each were tested for each strain except the ΔrecC mutant, which was tested with
only one biological replicate of 10 mice. Raw CFU and all urine and kidney data are displayed in the supplemental
material (Fig. S3). (C) Competitive outcomes of wild-type versus PSG mutant coinfections at 18 hpi. Circles represent
a single mouse. The horizontal line indicates the median log10(CI). An asterisk indicates that the median log10(CI)
is significantly different from the median log10(CI) of the control (wild type versus wild type) by the Mann-Whitney
U test (P  0.05). A single biological replicate of 5 to 7 mice was used for each competition except for the
wild-type–versus–wild-type comparison, which was carried out a second time. Raw CFU totals and all urine and
kidney data are displayed in the supplemental material (Fig. S4). (D) Bladder colonization by the PSG mutants in
single infections at 6 hpi. Circles represent a single mouse. The horizontal line indicates the median CFU/bladder.
An asterisk indicates that the median CFU/bladder is significantly different from that of the wild type by the
Mann-Whitney U test (P  0.05). A single biological replicate of 5 mice was conducted for each strain except for
the experiment with the wild type, which was carried out a total of three times. Kidney CFU data are displayed in
the supplemental material (Fig. S5).
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De novo arginine synthesis is required during competitive chronic UTI. Several
studies have suggested a role for arginine metabolism during UPEC UTI (37, 59–63).
However, argI is the only arg gene under positive selection in UPEC. To further
investigate the role of arginine metabolism and the function of ArgI during UTI, we
generated individual strains with mutations in argA and argG, two genes predicted to
encode metabolic enzymes that come biochemically before and after ArgI, respectively,
in the arginine biosynthetic pathway (Fig. 3A and Fig. S6) (47, 64). These genes are each
in monocistronic operons, and thus, their mutation is not predicted to induce polar
effects. An ΔargA mutant should have arginine synthesis disrupted upstream of the
substrate for ArgI, while an ΔargI mutant should have synthesis disrupted upstream of
the substrate for ArgG (Fig. 3A and Fig. S6) (47, 64). In agreement with previous work
in CFT073, all three arg mutants had similar phenotypes in vitro, exhibiting arginine
auxotrophy in minimal defined media and a lower cell density at entry into stationary
phase when grown in filtered pooled human urine (Fig. 3B and Fig. S6) (36). In
particular, high-cell-density growth in urine was restored by supplementation of argi-
nine or of the biosynthetic intermediates downstream of the mutated enzymatic step
(Fig. 3C and Fig. S6). We then tested the argA and argG mutants in competitive chronic
cystitis infections. Both the ΔargA and ΔargG mutants also had significant defects. In
particular, the ΔargG mutant was similar to the ΔargI mutant, in that they were rapidly
outcompeted by wild-type UTI89 in the urine samples [median log[CI]  4.0 by 14 dpi]
and had median log(CI) values from the bladders that were below 4.0 in mice at
28 dpi (Fig. 3D to F).
FIG 3 Arginine auxotrophs have competitive defects during chronic cystitis. (A) Simplified schematic of the conversion of glutamate to arginine (47, 64). Gray
boxes indicate the enzymes coded for by the genes that were deleted in this analysis. (B and C) Growth of arginine synthesis mutants in pooled, filtered human
urine (B) and pooled, filtered human urine supplemented 10 mM arginine (C). (D to F) Competitive colonization in the urinary tract of mice coinfected with
wild-type UTI89 and either ΔargA, (D), ΔargI (E), or ΔargG (F) mutants as indicated by the log10(CI) in the urine during the 28-day infection and in the bladder
and kidney tissue at sacrifice 28 dpi. Only mice with persistent bacteriuria of 104 CFU/ml were included in the analysis. Median bladder CIs of all three mutants
are significantly different from a hypothetical value of 0.0 by the Wilcoxon signed-rank test (P  0.05). Raw CFU and the log10(CI) values of the resolved
infections are displayed in the supplemental material (Fig. S7). All growth curves are the means of 4 technical replicates and are representative of experiments
conducted on different days and with different batches of urine. Values for competitive infections of arginine mutants versus the wild type are combinations
of at least two biological replicates of 10 mice per replicate.
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B2 strains of E. coli have a divergent allele of argI. The above-described exper-
iments with the ΔargA and ΔargG mutants argue that the role of ArgI in arginine
biosynthesis does not explain why it is evolving under positive selection. To understand
whether allelic variation (as opposed to deletion mutants) might provide further
insights (as it did with fimH), we assessed the conservation of the arg genes via a
pairwise comparison of arginine anabolic protein sequences from UTI89 and the
commensal E. coli isolate MC4100 (Fig. S8). In this comparison, the ArgI sequences had
20 variant residues out of 334 total amino acids (94% identity), while the other arginine
anabolic proteins were 98 to 100% identical between these isolates (Fig. S8). Interest-
ingly, the majority of the variable amino acids were spatially far from both the
enzymatic active site and the trimer interfaces (Fig. S8). We then examined the same arg
genes in a set of 2,274 publicly available E. coli genomes (all NCBI RefSeq assemblies as
of 26 April 2016). Again, argI was unique in that there was a largely B2-specific clade of
argI alleles which were separated from the other E. coli argI alleles by a relatively long
evolutionary branch (Fig. 4A). While B2-specific alleles were found in other arg genes,
FIG 4 B2 alleles of argI are distinct. (A) Approximate maximum-likelihood tree of unique argI alleles. The x axis indicates mutations per nucleotide (nt). Multiple
strains may have the same argI allele, and strains from different phylogroups may share the same allele. The phylogroup breakdown for each argI allele is shown
by colored circles at the right, with the size of the circle representing the number of strains and the color indicating the phylogroup of those strains, as shown
in the legend. The red branch of the argI tree on the left indicates a part of the tree that contains argI alleles that are mostly from B2 strains. Alleles found in
UTI89 and MG1655 are indicated. (B) Histograms of sequence divergence between argI alleles from different phylogroups. Random pairs of strains (the two
strains in each pair were from different phylogroups) were selected, and the maximum-likelihood distance between their argI genes was calculated. A total of
2,000 strain pairs for each phylogroup comparison were chosen, and the histogram of distances is plotted. The same process was repeated for different genes,
as indicated by the colors of the bars. The top graph only plots distances for pairs of strains in which neither strain was a B2 strain. The bottom graph plots
distances for pairs of strains where one of the strains was a B2 strain.
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they were not as clearly divergent from the other E. coli alleles. (Fig. 4B). The conserved
argI allele in the B2 clade of UPEC was significantly divergent (lowest nucleotide and
predicted amino acid identity) from argI alleles in the other E. coli clades. This dem-
onstrates that there is a conserved argI allele in the B2 clade, which was divergent from
argI in the other B2 clades. (Note that while sequence differences are required for
positive-selection detection algorithms to work, the existence of positive selection does
not necessarily correlate with sequence diversity in a given gene.)
A B2 allele of argI has an additional in vivo function during competitive chronic
UTI. To assess whether argI has an additional role during UTI aside from arginine
biosynthesis, we generated allelic replacement strains of UTI89, reintegrating the UTI89
(a B2 strain) or MC4100 (a non-B2 strain) allele of argI (designated argIUTI89 and
argIMC4100, respectively) into the original argI locus in UTI89 using a scarless cloning
technique (65). As expected, both argI alleles complemented all in vitro growth phe-
notypes (arginine auxotrophy in minimal media and low-density transition to stationary
phase in urine) (Fig. S8). To further test for subtle fitness defects, we performed
competitive in vitro growth assays between strains carrying either allele; again, no
differences were detectable between otherwise isogenic strains carrying these two argI
alleles (Fig. S8).
We then performed competitive, in vivo chronic infections between these strains
carrying the argIUTI89 and argIMC4100 alleles. These infections were performed as de-
scribed above, except they were allowed to proceed longer (63 dpi), as an initial pilot
experiment suggested that the full effect of the non-B2 argI allele had not manifested
by 28 dpi (data not shown). Remarkably, despite no detectable differences in vitro,
bacteria carrying argIUTI89 outcompeted those with the argIMC4100 allele in the urine,
bladders, and kidneys of chronically infected mice, reaching a median log10(CI) of 5.4
in the bladder at sacrifice at 63 dpi (Fig. 5 and Fig. S9). The strain carrying argIMC4100 was
nearly undetectable at this time. Importantly, at 28 dpi (matching the time point for
previous infections), the argIMC4100 strain was already significantly outcompeted by the
argIUTI89 strain in urine (Fig. 5).
FIG 5 The UTI89 variant of ArgI confers a competitive advantage over the MC4100 variant during chronic
cystitis. The competitive infection defect, indicated by log10(CI), of UTI89 carrying the argIMC4100 relative
to UTI89 carrying the argIUTI89 allele reintegrated into the chromosomal location of the original copy of
argI in the UTI89 genome in the urine during and in the bladder and kidney tissue at sacrifice after 63-day
coinfections is shown. Only mice with persistent bacteriuria of 104 CFU/ml were included in the
analysis. Median bladder log10(CI)s are significantly different from a hypothetical value of 0 by the
Wilcoxon signed-rank test with P values of 0.05. Antimicrobial resistance markers were swapped to
ensure that the resistance markers did not contribute to the phenotype, and the raw CFU data of all the
infections and the log10(CI) values of the resolved infections are displayed in the supplemental material
(Fig. S9). Each combination of argI allele and antimicrobial marker was assessed with a single biological
replicate of 10 mice each, resulting in two biological replicates comparing UTI89 argIUTI89 versus UTI89
argIMC4100.
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Different E. coli strains are known to differ in their propensity to cause disease in
humans (and other organisms), giving rise to disease syndrome-based terms such as
UPEC, enterohemorrhagic E. coli (EHEC), enteropathogenic E. coli (EPEC), avian patho-
genic E. coli (APEC), and neonatal meningitis-causing E. coli (NMEC), among others. In
other words, some E. coli strains are better adapted to survive in different habitats. A
firm genetic definition of these various types of pathogenic E. coli remains elusive;
however, most of the specific disease phenotypes have been attributed to known or
putative virulence factors, although many of these have not been fully experimentally
verified. UPEC, in particular, is a heterogeneous group of E. coli strains; while most are
found within the B2 and D clades, there remains substantial variation in gene content
even among B2 clade UPEC strains and no clear genetic signature of UPEC (66, 67). One
approach to identifying genetic adaptations that enable strains to cause urinary tract
infections (or other diseases) is to look for loci under positive selection (47, 68).
Positive selection is an evolutionary process whereby organisms with genetic
changes that increase fitness are more likely to survive or reproduce, thus increasing
the frequency of those changes in the population with time. In the context of virulence,
the genetic factors that enable some strains to cause a specific disease are those that
increase fitness and therefore should be evolving under positive selection. In the
specific case of UPEC, a direct connection between positive selection and virulence-
related genes has been posited (47, 68). One of the best-characterized examples in
UPEC is the fimH gene, which encodes the FimH tip adhesin that tips the type 1 pilus.
FimH has a critical role in the establishment of UTI as the primary binding determinant
for UPEC to specifically attach to and invade bladder epithelial cells by engaging
mannosylated surface proteins (17, 20, 69). The fimH gene is evolving under positive
selection (43, 46, 48, 68). Interestingly, the residues detected as increasing fitness
initially had no detectable in vitro role in binding to mannose (48). Subsequent work
showed that the amino acids under positive selection in FimH affected the dynamics of
switching between high- and low-affinity mannose binding states, which was a previ-
ously unappreciated step during UTI (49, 50).
In this study, we comprehensively tested a set of 29 additional PSGs that were
previously identified by comparing sequences of UPEC versus non-UPEC E. coli strains.
Deletion of 8 of these genes lowered fitness in a mouse model of chronic UTI. This
model mimics persistent infections experienced by some human patients. In this
model, high titers of UPEC are continuously present in the urine for the lifetime of the
animal or until the infection is cleared by antibiotics, implying that there may be a
strong selection for utilization of available nutrients (10, 12, 13). Interestingly, PSG
mutants demonstrated infection defects only when competing with an otherwise
isogenic wild-type strain. In humans, UTIs likely arise from the introduction of an
inoculum consisting of mixed bacterial species and E. coli strains from gastrointestinal
and vaginal reservoirs into the urinary tract (70–73). At the time of diagnosis, however,
UTIs are generally clonal infections consisting of high bacterial loads of a single strain
(74–76), implying that naturally occurring human UTIs may, in fact, also be competitive
infections. This competition will occur between E. coli and other bacteria in the
inoculum, which should include other members of the vaginal or perineal flora (such as
Lactobacillus); however, multiple strains of individual species (particularly E. coli) could
also be present in the inoculum, either closely or distantly related to one another,
mimicking the competitive experimental infections we have studied here.
The importance of growth and arginine metabolism led us to perform further
studies on argI (37, 59–63). Mutation of argI abolishes the ability of UPEC to synthesize
arginine, leading to auxotrophy for arginine. To test the hypothesis that arginine
metabolism is important in chronic UTI, we made deletion mutations in two other
genes, argA and argG, which also result in arginine auxotrophy. As expected, these
mutations also led to a fitness defect in chronic UTI. These results demonstrate that
amino acids, in particular arginine, are present at low levels in urine and that the ability
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to synthesize them de novo confers a competitive advantage to UPEC during UTI, but
they do not explain why argI is the only arginine synthesis gene evolving under positive
selection.
We therefore reexamined the sequence of argI and other arginine metabolic genes
in a broader set of 2,200 E. coli genome sequences, which indicated, consistent with
previous reports, that argI is evolving under positive selection and has specifically
diverged in B2 strains of E. coli. This divergence has a specific functional consequence
in vivo, as a UPEC strain carrying either a B2 allele or an A allele (a clade of E. coli
containing many commensal GI strains) has no auxotrophic phenotype for arginine;
however, the strain carrying the B2 allele outcompetes an isogenic strain carrying the
A allele as if the latter were an argI knockout. Interestingly, the clade D argI allele of E.
coli was not under positive selection, despite the fact that E. coli strains from this clade
are frequently observed causative agents of UTI (39). This finding suggests that there
may be multiple solutions that E. coli has evolved to facilitate persistence in the urinary
tract. We suggest that further positive selection analysis focusing on clade D E. coli
might reveal aspects of such an alterative mechanism.
These results with argI form a strong parallel with those previously observed for
fimH. Both genes have a clear function that is readily measured in vitro and known to
be important for UTI in vivo. In addition, both genes have allelic variants naturally found
among E. coli that do not obviously affect their function in vitro but result in strong
fitness defects in vivo. Similarly, it was recently shown that the oxidative fumarase FumC
is essential for fitness during UTI pathogenesis, but this essentiality appears to be
predominantly associated with the role FumC plays in coping with iron limitation, via
its ability to function enzymatically without an Fe-S cluster, rather than its specific role
in the tricarboxylic acid (TCA) cycle (77). We therefore hypothesize that, like with FimH
and FumC, a potential second, and possibly more subtle, function not currently
appreciated in vitro exists for ArgI. This second ArgI function would have specifically
evolved in B2, and its importance during chronic UTI would account for its being under
positive selection (though other environments or disease states may select for it as
well). The arginine synthesis step catalyzed by argI is situated at a branch point where
biosynthetic precursors can be shunted from arginine synthesis into the biosynthetic
pathway for several polyamines. The flux through the synthesis pathways of arginine
and of polyamines, which are multifunctional compounds that have been shown to
contribute to stress responses in UPEC, represent one potential mechanism by which
the B2 allele of argI contributes to fitness (61, 78, 79). Conversely, the enzymatic steps
catalyzed by ArgA and ArgG are relatively distal from this branch point and would likely
have less impact on the relative levels of arginine, ornithine, and the other arginine-
derived polyamines, suggesting one possible reason why argI is under positive selec-
tion in clade B2 E. coli but argA and argG are not.
We therefore conclude that positive selection analysis is indeed a powerful and
complementary technique for identifying genes important for virulence. The success
rate of PSG validation (deletion of 10/29 PSGs has a fitness defect, during chronic
infection [8 PSGs] and/or QIR formation [6 PSGs]) compares favorably to other methods
for identifying UPEC virulence genes, such as gene presence/absence analysis, candi-
date gene analysis (mostly targeted at “traditional” virulence factors or pathogenicity
islands), and transcriptomics analyses (38, 40, 80–84). Of note, other mutant screens,
such as Tn-seq, have very high validation rates. This is likely due to the fact that the
“putative virulence factors” identified in the initial large-scale mutagenesis Tn-seq
library screens are most often validated using the same pathogenicity model under
which they were first selected. PSG analysis is more similar to a bioinformatic genomic
comparison to determine presence/absence of genes in particular pathogenic strains
compared to nonpathogenic strains. These putative virulence genes and/or specific
gene alleles determined bioinformatically may be selected for in any of a number of
different environments or conditions under which these strains reside and/or cause
infection. Thus, the success of validating the role of any genomically identified candi-
date virulence factors is dependent upon which model they are tested in. We tested our
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PSGs in a UTI model and found that strains with deletions in any of 10 of them had
measurable UTI phenotypes. It may be possible that the other 19 PSGs for which we
found no UTI phenotype may provide a selective advantage in other habitats related to
UTI conditions, residence in the gastrointestinal tract (GIT), or vaginal reservoirs (85, 86).
Further, the particular alleles of PSGs may have phenotypes that cannot be elucidated
by testing deletion mutants but may require testing using allele swaps.
In addition, as shown for fimH and now argI, positive selection analysis potentially
captures alternative gene functions that are specifically required in vivo. More generally,
positive selection analysis is applicable to any infectious agent, sequences of which are
available at exponentially increasing rates. In particular, positive selection may be
especially useful for studying pathogenic processes that, like UTI, have stringent
bottlenecks and strong founder effects, such as those of HIV, Salmonella enterica
serovar Typhimurium, and Borrelia burgdorferi (87–90).
MATERIALS AND METHODS
Ethics statement. All animal experiments were conducted in accordance with the National Institutes
of Health guidelines for the housing and care of laboratory animals as well as institutional regulations
after pertinent review and approval by the Animal Studies Committee at the Washington University
School of Medicine (protocol number 21080276). Human urine used for growth determination was
collected from healthy consenting volunteers according to Hultgren lab human studies protocol number
201207143.
Media, reagents, and mutant generation. The UPEC strains used in this study are all derivatives of
the human cystitis isolate UTI89 and are listed in Table S1 (17, 91). In general, bacteria were grown and
propagated in Luria-Bertani (LB) broth and plated for isolation on LB agar (BD). Where necessary, the
medium was supplemented with 50 g/ml kanamycin, 50 g/ml spectinomycin, 100 g/ml ampicillin,
and/or 1 mM isopropyl -D-1-thiogalactopyranoside (Gold-Bio). Human urine was collected from at least
2 healthy volunteers and filter sterilized through a 0.22-m filter (Millipore). Biological replicates of
growth curves were conducted with different batches of urine collected on different days. Where
indicated, urine was supplemented with 10 mM ornithine, citrulline, or arginine (Sigma-Aldrich).
All deletion mutants were generated in the prototypical cystitis isolate UTI89 using the Red
recombinase system (92, 93). The allelic replacement of argI was performed using a previously described,
Red recombinase-based negative-selection system (65). To facilitate in vivo competition assays, kana-
mycin or chloramphenicol resistance markers were inserted into the HK site using the standard Red
recombinase protocol (49, 94). All deletion and allelic replacement mutants were confirmed by Sanger
sequencing.
Growth curves. Growth curves were acquired on a Tecan infinite M200 Pro (Tecan). Cultures were
diluted 1:1,000 into 200 l of the appropriate medium with arginine, citrulline, or ornithine supplemen-
tation where appropriate in CellStar clear polystyrene 96-well flat-bottom plates (Greiner Bio-One) and
incubated at 37°C with shaking for 10 to 15 h. Each curve is the average of 4 technical replicates, and the
curves are representative of at least 3 independent experiments.
Hemagglutination. Hemagglutination assays were performed as described previously (95, 96).
Mouse models of acute and chronic UTI. Female, 6- to 7-week-old C3H/HeN HSD mice were
acquired from Envigo Laboratories and allowed to acclimate to the Washington University Medical
School animal housing facility for 1 week. General infections were performed transurethrally as described
previously (11). For single-strain infections, the inoculum contained 2  107 to 4  107 CFU of a
derivative of UTI89 containing a chromosomally integrated kanamycin resistance gene either at the
pathogenically neutral lambda attP site (94) or at the site of the desired PSG or arginine synthesis gene.
Competitive infections were inoculated with 2  107 to 4  107 CFU each of a derivative of UTI89
containing a chromosomally integrated spectinomycin resistance gene at the pathogenically neutral HK
site (16) and one of the kanamycin resistance (Kmr) gene-containing strains mentioned above, including
the wild type to control for pleotropic effects of the kanamycin and spectinomycin resistance genes on
fitness during pathogenesis. Allele swap experiments assessing the impact argI variation were performed
with UTI89 argIUTI89  Kmr in the HK site competing against UTI89 argIMC4100  Cmr (chloramphenicol
resistance gene) in the HK site and with UTI89 argIUTI89  Cmr in the HK site competing against UTI89
argIMC4100  Kmr in the HK site.
UT tissue burdens were determined as described previously (11). For long-term infections,
bacteriuria was monitored as described previously at various time points from 1 to 63 dpi (11).
Where appropriate, competitive indices were determined as log10[(Specr CFU/Kanr CFU)/inoculum
(Specr CFU/Kanr CFU)] or log10[(argIMC4100 CFU/argIUTI89 CFU)/inoculum (argIMC4100 CFU/argIUTI89
CFU)] to control for variations in the initial inoculum.
Phylogenetic analysis of arginine anabolism. All RefSeq assemblies listed for Escherichia coli (as of
26 April 2016) were downloaded from NCBI GenBank. For a given gene, orthologs were identified using
TBLASTN (97); the UTI89 allele of that gene was used as the query against each of the individual
assembled genomes. For each genome, only the best single hit that was at least 90% identical over at
least 90% of the total length of the UTI89 allele was kept. Unique alleles (based on DNA sequence) were
aligned as translated protein sequences; then this protein alignment was imposed on the DNA se-
quences. Approximate maximum-likelihood trees were created using FastTree 2 (with the –nt and – gtr
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command line switches) (98). Phylogroups were assigned using an in silico implementation of a triplex
PCR (99). All analyses utilized custom Perl scripts. Visualization was done in R (version 3.2.2; https://www
.R-project.org) using the ggtree (100), ape (101), and ggplot2 (102) packages.
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